BRAF and central nervous system cancer: Recently the combination of Dabrafenib + Trametinib received the Food and Drug Administration (FDA) approval in adult and pediatric solid tumors (except colorectal cancer) based on a demonstration of anti-tumor activity in more than 20 different cancer histologies including BRAF V600 mutant low-grade glioma (LGG) and high-grade glioma (HGG)6–8.